Landscape Capital Management L.L.C. Purchases 7,693 Shares of ResMed Inc. (NYSE:RMD)

Landscape Capital Management L.L.C. increased its position in ResMed Inc. (NYSE:RMD - Free Report) by 59.6% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 20,609 shares of the medical equipment provider's stock after purchasing an additional 7,693 shares during the quarter. ResMed accounts for 0.5% of Landscape Capital Management L.L.C.'s portfolio, making the stock its 29th largest position. Landscape Capital Management L.L.C.'s holdings in ResMed were worth $4,713,000 at the end of the most recent quarter.

A number of other large investors have also added to or reduced their stakes in the company. First Horizon Advisors Inc. increased its holdings in ResMed by 285.1% during the 4th quarter. First Horizon Advisors Inc. now owns 593 shares of the medical equipment provider's stock worth $136,000 after purchasing an additional 439 shares during the last quarter. Peak Financial Advisors LLC bought a new stake in shares of ResMed in the fourth quarter worth $2,972,000. Principal Financial Group Inc. increased its stake in shares of ResMed by 2.9% in the third quarter. Principal Financial Group Inc. now owns 186,776 shares of the medical equipment provider's stock worth $45,596,000 after buying an additional 5,284 shares during the last quarter. Spire Wealth Management raised its holdings in ResMed by 11.3% in the fourth quarter. Spire Wealth Management now owns 10,800 shares of the medical equipment provider's stock valued at $2,470,000 after acquiring an additional 1,100 shares in the last quarter. Finally, Asset Management One Co. Ltd. boosted its stake in ResMed by 2.8% during the 4th quarter. Asset Management One Co. Ltd. now owns 60,489 shares of the medical equipment provider's stock valued at $14,105,000 after acquiring an additional 1,629 shares during the last quarter. 54.98% of the stock is owned by institutional investors and hedge funds.

Remove Ads

ResMed Stock Down 0.2 %

ResMed stock traded down $0.33 during trading hours on Wednesday, hitting $204.21. The company had a trading volume of 319,371 shares, compared to its average volume of 1,010,084. The firm's fifty day moving average is $228.02 and its 200-day moving average is $236.22. The firm has a market capitalization of $29.99 billion, a P/E ratio of 24.11, a price-to-earnings-growth ratio of 1.53 and a beta of 0.75. ResMed Inc. has a fifty-two week low of $172.19 and a fifty-two week high of $263.05. The company has a debt-to-equity ratio of 0.13, a current ratio of 3.33 and a quick ratio of 2.29.

ResMed (NYSE:RMD - Get Free Report) last issued its earnings results on Thursday, January 30th. The medical equipment provider reported $2.43 earnings per share for the quarter, topping the consensus estimate of $2.29 by $0.14. ResMed had a return on equity of 26.17% and a net margin of 25.34%. On average, research analysts forecast that ResMed Inc. will post 9.47 earnings per share for the current year.

ResMed Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Thursday, March 20th. Investors of record on Thursday, February 13th were given a dividend of $0.53 per share. This represents a $2.12 annualized dividend and a yield of 1.04%. The ex-dividend date was Thursday, February 13th. ResMed's payout ratio is presently 25.03%.

Insider Buying and Selling at ResMed

In related news, Director Peter C. Farrell sold 2,000 shares of ResMed stock in a transaction on Wednesday, April 2nd. The shares were sold at an average price of $219.74, for a total value of $439,480.00. Following the completion of the sale, the director now owns 73,218 shares of the company's stock, valued at approximately $16,088,923.32. The trade was a 2.66 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Kaushik Ghoshal sold 9,745 shares of the stock in a transaction on Monday, March 10th. The stock was sold at an average price of $239.31, for a total transaction of $2,332,075.95. Following the transaction, the insider now directly owns 9,725 shares in the company, valued at $2,327,289.75. The trade was a 50.05 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 41,004 shares of company stock worth $9,618,128 over the last ninety days. 0.71% of the stock is currently owned by insiders.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on RMD shares. StockNews.com lowered shares of ResMed from a "buy" rating to a "hold" rating in a research note on Wednesday, April 2nd. The Goldman Sachs Group started coverage on ResMed in a research note on Thursday, January 16th. They set a "buy" rating on the stock. Needham & Company LLC reiterated a "hold" rating on shares of ResMed in a research report on Friday, January 31st. Piper Sandler boosted their price target on ResMed from $252.00 to $260.00 and gave the company a "neutral" rating in a report on Friday, January 31st. Finally, Citigroup upgraded ResMed from a "neutral" rating to a "buy" rating in a research note on Wednesday, March 5th. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating, seven have issued a buy rating and two have issued a strong buy rating to the company's stock. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus target price of $249.73.

About ResMed

ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; and NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry over several nights.